Cardiovascular toxicity of angiogenesis inhibitors in treatment of malignancy: a systematic review and meta-analysis

Angiogenesis is a key factor for tumor growth and survival[1,2]. Accordingly, angiogenesis inhibition is an attractive target for suppressing tumour growth, and angiogenesis inhibitors have been shown to improve outcomes in a variety of malignancies. Most angiogenesis inhibitors exert their effect by inhibiting the vascular endothelial growth factor (VEGF) signalling pathway, via one of two mechanisms[3,4]. The first is direct inhibition of the VEGF ligand’s ability to bind to its target receptor.

from #AlexandrosSfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/2iQfXun
via IFTTT